# US 2002/0058288 A1 · Toxoplasma gondii glycoconjugates

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2002/0058288 A1
- Document ID: US20020058288A1
- Status: Published application
- Kind: A1
- Application number: 09/043,255
- Filed: 1998-08-06
- Published: 2002-05-16
- Earliest claimed: 1995-09-15
- Inventors: MARCUS JOSEPHUS MARIE KOOLEN; JAN BAS LOUIS DAMM; BORIS STRIEPEN; RALPH T. SCHWARZ
- Web page: https://patentgrep.com/patent/US20020058288A1

## CPC

- A61K 39/002: Protozoa antigens
- A61P 33/00: Antiparasitic agents
- A61P 33/02: Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- C07H 3/06: Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
- C07K 16/20: from protozoa
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention relates to a glycoconjugate immunoreactive with Toxoplasma gondii antibodies, (monoclonal) antibodies against these glycoconjugates, and cell lines capable of producing monoclonal antibodies. The invention is further concerned with immunochemical reagents and methods for the detection of T. gondii or antibodies directed agains T. gondii. Furthermore the invention relates to a therapeutic reagent for the inhibition of replication of T. gondii parasites and a method for the production of a live attenuated T. gondii vaccine. It has now been found, and in contrast with earlier publications in this art, that several glycoconjugates are immunoreactive with Toxoplasma gondii specific antibodies comprising a glycan core structure having general formula (I) wherein R1=Hydrogen, —PO 3 —CH 2 —CH 2 —NH 2 (ethanolamine-phosphate), or —PO 3 —CH 2 —CH 2 —NH—X, wherein X=a T. gondii specific antigen; wherein R2=±—O—R4, ±(1-4)-O-anhydromannitol or ±(1-4)-O-glucoseamine optionally ±(1-6)-linked to the inositol moiety of a phosphatidylinositol membrane anchor; wherein R3=a monosaccharide moiety, wherein R4=Hydrogen or —L—R5, wherein L=a bivalent organic radical and R5=a functional group that allows coupling to a carrier. A preferred embodiment of the monosaccharide moiety is a hexose moiety, more preferred is a glucose moiety, and most preferred is a glucose moiety which is bonded to the GalNAc-moiety by an ±1,4 glycosidic bond. It has been found that the glycoconjugates according to the present invention are particularly suitable for diagnosing T. gondii infected humans.

## Claims

### Claim 1

Glycoconjugate comprising a glycan core structure having the general formula
2
wherein R1=Hydrogen, —PO3−—CH2—CH2—NH2 (ethanolamine-phosphate), or —PO3-CH2—CH2—NH—X, wherein X=a T. gondii specific antigen;
wherein R2=α—O—R4, α(1-4)-O-anhydromannitol or a( 1-4)-O-glucoseamine optionally α(1-6)-linked to the inositol moiety of a phosphatidylinositol membrane anchor;
wherein R3=a monosaccharide moiety,
wherein R4=Hydrogen or —L—R5, wherein L=a bivalent organic radical and
R5=a functional group that allows coupling to a carrier.

### Claim 2 (depends on 1)

Glycoconjugate according to claim 1, characterized in that said monosaccharide moiety is a hexose moiety.

### Claim 3 (depends on 2)

Glycoconjugate according to claim 2, characterized in that said hexose moiety is a glucose moiety.

### Claim 4 (depends on 3)

Glycoconjugate according to claim 3, characterized in that said glucose moiety is bonded to the GalNAc-moiety by an α-1,4 glycosidic bond.

### Claim 5 (depends on 1, 2, 3, 4)

Glycoconjugate according to any one of claims 1-4, characterized in that said glycoconjugate comprises the following structure:
3
wherein X=a T. gondii specific antigen.

### Claim 6 (depends on 1, 2, 3, 4, 5)

Glycoconjugate according to any of claims 1-5, characterized in that said glycoconjugate is obtainable from T. gondii tachyzoites by an isolation procedure comprising the steps of:
disruption of the tachyzoite membrane, and,
extracting the resulting tachyzoite suspension with a chloroform/methanol/water (C/M/W: 1/1/0.3 v/v) mixture.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

Glycoconjugate according to any of claims 1-6, characterized in that said glycoconjugate is immunoreactive with human monoclonal antibodies produced by the immortalized cell-line deposited with the European Collection of Animal Cell Cultures (ECACC), Porton Down (UK), under deposit number 95090608 or 95090609.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

Antibody directed against a T. gondii glycoconjugate, characterized in that said antibody is immunoreactive with the glycoconjugate according to any of claims 1-7.

### Claim 9 (depends on 8)

Antibody according to claim 8, characterized in that said antibody is a monoclonal antibody.

### Claim 10

Monoclonal antibody which binds to an epitope of a T. gondii glycoconjugate, which epitope is recognized by monoclonal antibody TOX.HuOT-1 or TOX.HuOT-2 produced by the hybridoma cell lines deposited with the European Collection of Animal Cell Cultures (ECACC), Porton Down (UK), under deposit No. 95090608 and 95090609 respectively.

### Claim 11

Monoclonal antibody TOX.HuOT-1 or TOX.HuOT-2 produced by the hybridoma cell lines deposited with the European Collection of Animal Cell Cultures (ECACC), Porton Down (UK), under deposit No. 95090608 and 95090609 respectively.

### Claim 12 (depends on 9, 10, 11)

Immortalized cell line capable of producing monoclonal antibodies according to any of claims 9-11.

### Claim 13

Immortalized cell line deposited with the European Collection of Animal Cell Cultures (ECACC), Porton Down (UK), under deposit No. 95090608 and 95090609 respectively.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7)

Immunochemical reagent, characterized in that it comprises a glycoconjugate according to any of claims 1-7.

### Claim 15 (depends on 8, 9, 10, 11)

Immunochemical reagent, characterized in that it comprises an antibody according to any of claims 8-11.

### Claim 16 (depends on 9, 10, 11)

A method for the detection of T. gondii in a test fluid, characterized in that said test fluid is contacted with an antibody according to any of claims 9-11 whereafter the presence of immune complexes is detected.

### Claim 17 (depends on 14)

A method for the detection of antibodies directed against T. gondii in a test fluid, characterized in that an immunochemical reagent according to claim 14 is brought into contact with the test fluid and the presence of immune complexes formed in the test fluid is detected.

### Claim 18 (depends on 15)

A method for the detection of T. gondii in a test fluid, characterized in that an immunochemical reagent according to claim 15 is brought into contact with the test fluid, whereto antibodies directed to T. gondii are brought into contact, and the presence of immune complexes formed is detected.

### Claim 19 (depends on 14)

A test-kit for the detection of T. gondii infection, characterized in that said test-kit comprises an immunochemical reagent according to claim 14.

### Claim 20 (depends on 15)

A test-kit for the detection of T. gondii infection characterized in that said test-kit comprises an immunochemical reagent according to claim 15.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7)

A therapeutic reagent for the inhibition of replication of T. gondii parasites, characterized in that said therapeutic reagent comprises a specific inhibitor which inhibits the biosynthesis of the glycoconjugate according to any of claims 1-7.

### Claim 22 (depends on 21)

A method for the production of a live-attenuated T. gondii vaccine, characterized in that the surface expression of GPI-anchored antigens is blocked or inhibited by the therapeutic reagent according to claim 21.
